Wellington Management Group LLP Purchases 1,910 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

Wellington Management Group LLP raised its position in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 9.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 22,738 shares of the company’s stock after buying an additional 1,910 shares during the quarter. Wellington Management Group LLP’s holdings in BeOne Medicines were worth $6,480,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Mariner LLC increased its position in BeOne Medicines by 3.8% during the 4th quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after buying an additional 32 shares in the last quarter. CWM LLC grew its stake in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the last quarter. Steadtrust LLC grew its stake in shares of BeOne Medicines by 3.7% during the second quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock worth $399,000 after acquiring an additional 50 shares during the last quarter. Benjamin Edwards Inc. increased its holdings in shares of BeOne Medicines by 8.0% during the fourth quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock valued at $210,000 after acquiring an additional 51 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of BeOne Medicines by 16.4% during the first quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock valued at $110,000 after acquiring an additional 52 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on ONC shares. Citizens Jmp lifted their target price on shares of BeOne Medicines from $396.00 to $405.00 and gave the stock a “market outperform” rating in a research note on Thursday, August 6th. Citigroup restated an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Morgan Stanley reaffirmed an “overweight” rating on shares of BeOne Medicines in a report on Thursday, August 6th. Zacks Research upgraded shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Finally, Royal Bank Of Canada dropped their price objective on shares of BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $402.14.

Insiders Place Their Bets

In other news, CEO John Oyler sold 54,892 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $358.15, for a total value of $19,659,569.80. Following the sale, the chief executive officer owned 240,743 shares in the company, valued at $86,222,105.45. This represents a 18.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Chan Lee sold 2,666 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $360.00, for a total transaction of $959,760.00. Following the transaction, the senior vice president directly owned 812 shares of the company’s stock, valued at approximately $292,320. This trade represents a 76.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 579,683 shares of company stock worth $190,541,846. Company insiders own 6.19% of the company’s stock.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $351.48 on Wednesday. The business’s 50 day moving average price is $336.64 and its 200 day moving average price is $311.42. The firm has a market cap of $38.59 billion, a P/E ratio of 61.88 and a beta of 0.51. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $253.95 and a 52 week high of $385.22. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The company had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. On average, sell-side analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 earnings per share for the current year.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.